ARGX-111 

ARGX-111 is an afucosylated anti-MET antibody. ARGX-111 blocks HGF-dependent and -independent signaling, downregulating MET expression on the tumor cell surface. ARGX-111 depletes MET-expressing circulating tumor cells through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thereby inhibiting tumor metastasis. ARGX-111 depletes circulating tumor cells and inhibits bone and lung metastasis in an orthotopic mouse model of metastatic breast cancer. ARGX-111 is promising for research in breast cancer and other cancers^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

HGFR/c-Met

ARGX-111 binds to native MET with an EC₅₀ ranging from 0.1 nmol/L to 0.7 nmol/L, competes with HGF displaying an IC₅₀ of 1.3 nmol/L and an IMAX of 95%^[1].
ARGX-111 inhibits HGF-induced MET autophosphorylation in A549 cells (IC₅₀ = 5.3 nmol/L, IMAX = 74%), inhibits MET autophosphorylation in both MKN-45 cells (IC₅₀ = 0.2 nmol/L, IMAX = 63%) and EBC-1 cells (IC₅₀ = 12.7 nmol/L, IMAX = 69%)^[1].
ARGX-111 neutralizes the promigratory effect of HGF, inhibits HGF-dependent colony formation by 78% in A549 cells^[1].
ARGX-111 (1-10 nM/L) inhibits HGF-induced branched tubule formation in SV40 T-antigen-transformed LOC human kidney epithelial cell spheroids^[1].
ARGX-111 (0.1-100 h) promotes a rapid decrease in MET expression in MKN-45, EBC-1 and MDA-MB 231 cells^[1].
ARGX-111 (24-48 h) does not promote receptor shedding but reduced total MET protein levels in MKN-45 cells^[1].
ARGX-111 (0-1000 nM/L) induces dose-dependent lysis in MKN-45, NCI-H441, A549 cells^[1].
ARGX-111 induces antibody-dependent cellular phagocytosis (ADCP) in MKN-45 and 786-O cells^[1].
ARGX-111 (0-667 nM/L) promotes dose-dependent ADCC in ALDH-1-sorted MDA-MB-231, CRCM168, CRCM174, CRCM389 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

4233  [NCBI]

P08581

HGFR/c-Met

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

N/A

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hultberg A, et al. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling. Cancer Res. 2015 Aug 15;75(16):3373-83.

  [2]. V Morello, et al. Abstract P2-05-17: ARGX-111 depletes MET-expressing circulating tumor cells via enhanced ADCC, resulting in inhibition of metastasis. Cancer Res 15 February 2016; 76 (4_Supplement): P2–05–17.